HOME
기자가 쓴 기사 더보기
(편집자 주 - 2010년 9월 25일 미국 FDA에서 보내온 에포젠 (Epogen) 과 프로크리트 (Procrit) 리콜 관련 내용입니다.)
Epogen and Procrit (epoetin alfa): Recall - Particulate Matter in Vials
AUDIENCE: Risk Manager, Oncology, Nephrology
ISSUE: Amgen and FDA notified healthcare professionals that certain lots of Epogen and Procrit (Epoetin alfa) vials are being recalled as a precaution, because the vials may contain extremely thin glass flakes (lamellae) that are barely visible.
The potential serious adverse events resulting from the use of a sterile injectable product with particulates by the intravenous route include embolic, thrombotic and other vascular events (e.g., phlebitis), and by the subcutaneous route include foreign body granuloma, local injection site reactions, and increased immunogenicity.
BACKGROUND: The products are indicated for the treatment of anemia related to HIV therapy, chronic renal failure, and chemotherapy.
The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.
The affected product lot numbers and expiration dates are included in the table in the firm press release.
RECOMMENDATIONS: Amgen has initiated recall letters which include instructions to return the referenced product to the returned goods service provider.
| 인기기사 | 더보기 + |
-
1 “간의 벽 깨졌다” 올릭스 2.0, 비만·CNS siRNA 신약개발 드라이브 -
2 첨단바이오 제품화 병목 풀릴까…식약처, ‘Bio Rise-Up’ 본격 가동 -
3 지아이이노베이션,차세대 폐동맥고혈압 치료제 ‘GI-214’ 특허 출원 -
4 "과다 의료이용, 진료 단계서 막는다"…심평원, 실시간 관리 도입 -
5 지분 쪼개기·교차 거래 꼼수 막아라… 의료기기 유통 현장의 매서운 지적들 -
6 삼성바이오에피스, 중국 바이오 혁신센터와 연구 협력 추진 -
7 차바이오텍,판교 제2테크노밸리 CGB 대규모 ‘K-Bio CIC’ 구축…2026년 가동 -
8 SK바사, 171억 규모 자사주 매입 통해 임직원 대상 ‘RSU’ 제도 도입 -
9 아이오니스 "RNA 치료제, 마지막 퍼즐 ‘독성’ 해법 찾았다…RNA 신약 새 시대" -
10 노바티스 경구 만성 담마진 치료제 EU서 승인
| 인터뷰 | 더보기 + |
| PEOPLE | 더보기 + |
| 컬쳐/클래시그널 | 더보기 + |
|
서울시 서초구 서초대로 115 정다운빌딩 4층 TEL : 02-3270-0114 FAX : 02-3270-0189 E-mail : webmaster@yakup.com |
발행일 : 1954. 03. 29 등록일 : 2016. 05. 02 대표이사 : 함태원 발행 · 편집인 : 함태원 등록번호 : 서울,아04071 |
사업자등록번호 : 106-81-10940 통신사업자신고번호 : 제2022-서울서초-2586호 청소년보호책임자 : 이종운
Copyright © Yakup.com All rights reserved.
|
- 약업신문 편집국 기자 news@yakup.com
- 입력 2010.09.26 02:16 수정 2010.09.26 03:39
(편집자 주 - 2010년 9월 25일 미국 FDA에서 보내온 에포젠 (Epogen) 과 프로크리트 (Procrit) 리콜 관련 내용입니다.)
Epogen and Procrit (epoetin alfa): Recall - Particulate Matter in Vials
AUDIENCE: Risk Manager, Oncology, Nephrology
ISSUE: Amgen and FDA notified healthcare professionals that certain lots of Epogen and Procrit (Epoetin alfa) vials are being recalled as a precaution, because the vials may contain extremely thin glass flakes (lamellae) that are barely visible.
The potential serious adverse events resulting from the use of a sterile injectable product with particulates by the intravenous route include embolic, thrombotic and other vascular events (e.g., phlebitis), and by the subcutaneous route include foreign body granuloma, local injection site reactions, and increased immunogenicity.
BACKGROUND: The products are indicated for the treatment of anemia related to HIV therapy, chronic renal failure, and chemotherapy.
The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.
The affected product lot numbers and expiration dates are included in the table in the firm press release.
RECOMMENDATIONS: Amgen has initiated recall letters which include instructions to return the referenced product to the returned goods service provider.
무단 전재·복사·배포 등을 금지합니다.